XML 47 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Disaggregation of Revenue [Line Items]    
Total revenues $ 12,982 $ 35,340
Americas    
Disaggregation of Revenue [Line Items]    
Total revenues 2,584 3,732
EMEA    
Disaggregation of Revenue [Line Items]    
Total revenues 3,089 4,127
APAC    
Disaggregation of Revenue [Line Items]    
Total revenues 7,309 27,481
Product revenue    
Disaggregation of Revenue [Line Items]    
Total revenues 8,364 30,690
Research and development revenue    
Disaggregation of Revenue [Line Items]    
Total revenues 4,618 4,650
Performance Enzymes    
Disaggregation of Revenue [Line Items]    
Total revenues 9,486 33,099
Performance Enzymes | Americas    
Disaggregation of Revenue [Line Items]    
Total revenues 918 2,553
Performance Enzymes | EMEA    
Disaggregation of Revenue [Line Items]    
Total revenues 1,259 3,065
Performance Enzymes | APAC    
Disaggregation of Revenue [Line Items]    
Total revenues 7,309 27,481
Performance Enzymes | Product revenue    
Disaggregation of Revenue [Line Items]    
Total revenues 8,364 30,690
Performance Enzymes | Research and development revenue    
Disaggregation of Revenue [Line Items]    
Total revenues 1,122 2,409
Novel Biotherapeutics    
Disaggregation of Revenue [Line Items]    
Total revenues 3,496 2,241
Novel Biotherapeutics | Americas    
Disaggregation of Revenue [Line Items]    
Total revenues 1,666 1,179
Novel Biotherapeutics | EMEA    
Disaggregation of Revenue [Line Items]    
Total revenues 1,830 1,062
Novel Biotherapeutics | APAC    
Disaggregation of Revenue [Line Items]    
Total revenues 0 0
Novel Biotherapeutics | Product revenue    
Disaggregation of Revenue [Line Items]    
Total revenues 0 0
Novel Biotherapeutics | Research and development revenue    
Disaggregation of Revenue [Line Items]    
Total revenues $ 3,496 $ 2,241